Login to Your Account



Clinic Roundup


Tuesday, February 7, 2012
• Neurelis Inc., of San Diego, said the FDA cleared the investigational new drug application for NRL-1, an intranasal diazepam formulation, to begin clinical trials in acute breakthrough seizures. Delivered through a commercially available nasal sprayer, NRL-1 is being developed to manage patients who require intermittent use of diazepam to control bouts of acute repetitive seizure activity outside the hospital setting.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription